# US 2014/0271712 A1 · Methods and compositions for norovirus blockade epitopes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271712 A1
- Document ID: US20140271712A1
- Status: Published application
- Kind: A1
- Application number: 14/213,469
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: The University of North Carolina at Chapel Hill
- Applicants: The University of North Carolina at Chapel Hill
- Inventors: Ralph Steven Baric; Lisa Chon Lindesmith; Kari Moore Debbink; Eric Francis Donaldson; Jesica Anne Swanstrom
- Web page: https://patentgrep.com/patent/US20140271712A1

## CPC

- C07K 14/005: from viruses
- G01N 33/56983: {Viruses}
- C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- G01N 2333/08: RNA viruses
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods and compositions comprising a chimeric norovirus capsid protein comprising a norovirus VP1 major capsid protein backbone comprising a norovirus epitope selected from the group consisting of: a) Epitope A; b) Epitope B; c) Epitope C; d) Epitope D; e) Epitope E; f) Epitope F; and g) any combination of (a) through (f) above, wherein the norovirus epitope is from a norovirus strain that is different from the norovirus VP1 major capsid protein backbone.

## Claims

### Claim 1

A chimeric norovirus capsid protein comprising a norovirus VP1 major capsid protein backbone comprising a norovirus epitope selected from the group consisting of:
a) Epitope A;
b) Epitope B;
c) Epitope C;
d) Epitope D;
e) Epitope E;
f) Epitope F; and
g) any combination of (a) through (f) above,
wherein the norovirus epitope is from a norovirus strain that is different from the norovirus VP1 major capsid protein backbone.

### Claim 2 (depends on 1)

The chimeric norovirus capsid protein of claim 1, wherein the norovirus VP1 major capsid protein backbone is from a genogroup GII, genotype 4 (GII.4) strain.

### Claim 3 (depends on 2)

The chimeric norovirus capsid protein of claim 2, wherein the norovirus VP1 major capsid protein backbone is from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009, or GII.4.2012.

### Claim 4

A synthetic backbone molecule comprising a norovirus epitope selected from the group consisting of:
a) Epitope A;
b) Epitope B;
c) Epitope C;
d) Epitope D;
e) Epitope E;
f) Epitope F; and
g) any combination of (a) through (f) above, wherein the backbone molecule allows for formation of a conformational epitope.

### Claim 5

A norovirus P particle comprising a norovirus epitope selected from the group consisting of:
a) Epitope A;
b) Epitope B;
c) Epitope C;
d) Epitope D;
e) Epitope E;
f) Epitope F; and
g) any combination of (a) through (f) above, wherein the epitope(s) are presented on the P particle surface.

### Claim 6

A mimitope comprising a norovirus epitope selected from the group consisting of:
a) Epitope A;
b) Epitope B;
c) Epitope C;
d) Epitope D;
e) Epitope E;
f) Epitope F; and
g) any combination of (a) through (f) above.

### Claim 7 (depends on 1)

The chimeric norovirus capsid protein of claim 1, comprising Epitope A (amino acids 294, 296, 297, 298, 368 and 372) from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009 or GII.4.2012, wherein Epitope A is from a norovirus strain different from the norovirus VP1 major capsid protein backbone.

### Claim 8 (depends on 1)

The chimeric norovirus capsid protein of claim 1, comprising Epitope B (amino acids 333 and 382) from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009 or GII.4.2012, wherein Epitope B is from a norovirus strain different from the norovirus VP1 major capsid protein backbone.

### Claim 9 (depends on 1)

The chimeric norovirus capsid protein of claim 1, comprising Epitope C (amino acids 340 and 376) from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009 or GII.4.2012, wherein Epitope C is from a norovirus strain different from the norovirus VP1 major capsid protein backbone.

### Claim 10 (depends on 1)

The chimeric norovirus capsid protein of claim 1, comprising Epitope D (amino acids 393, 394 and 395) from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009 or GII.4.2012, wherein Epitope D is from a norovirus strain different from the norovirus VP 1 major capsid protein backbone.

### Claim 11 (depends on 1)

The chimeric norovirus capsid protein of claim 1, comprising Epitope E (amino acids 407, 412 and 413) from GII.4.1974, GII.4.1987, GII.4.1997, GII.4.2002a, GII.4.2002, GII.4.2004, GII.4.2005, GII.4.2006, GII.4.2007, GII.4.2008s, GII.4.2008a, GII.4.2009 or GII.4.2012, wherein Epitope E is from a norovirus strain different from the norovirus VP 1 major capsid protein backbone.

### Claim 12 (depends on 2)

The chimeric norovirus capsid protein of claim 2, wherein the norovirus VP1 major capsid protein backbone is from GII.4.2006.

### Claim 13 (depends on 12)

The chimeric norovirus capsid protein of claim 12, comprising Epitope A from GII.4.1987 and Epitope E from GII.4.2002.

### Claim 14 (depends on 1)

An isolated nucleic acid molecule encoding the chimeric norovirus capsid protein of claim 1.

### Claim 15 (depends on 14)

A vector comprising the nucleic acid molecule of claim 14.

### Claim 16 (depends on 14)

A Venezuelan Equine Encephalitis (VEE) replicon particle (VRP) comprising the nucleic acid molecule of claim 14.

### Claim 17 (depends on 1)

A virus like particle (VLP) comprising the chimeric norovirus capsid protein of claim 1.

### Claim 18 (depends on 1)

A composition comprising the chimeric norovirus capsid protein of claim 1 in a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method of producing an immune response to a norovirus in a subject, comprising administering to the subject an effective amount of the chimeric norovirus capsid protein of claim 1.

### Claim 20 (depends on 1)

A method of treating a norovirus infection in a subject in need thereof, comprising administering to the subject an effective amount of the chimeric norovirus capsid protein of any of claim 1.

### Claim 21 (depends on 1)

A method of preventing a norovirus infection in a subject, comprising administering to the subject an effective amount of the chimeric norovirus capsid protein of claim 1.

### Claim 22 (depends on 1)

A method of protecting a subject from the effects of norovirus infection, comprising administering to the subject an effective amount of the chimeric norovirus capsid protein of claim 1.

### Claim 23 (depends on 1)

A method of detecting a neutralizing antibody to a norovirus, the method comprising determining whether an antibody binds to the chimeric norovirus capsid protein of claim 1, wherein binding by the antibody to the chimeric norovirus capsid protein indicates that the antibody is a neutralizing antibody to a norovirus.

### Claim 24 (depends on 1)

A method of identifying a neutralizing antibody to a norovirus, comprising:
(a) contacting an antibody with the chimeric norovirus capsid protein of claim 1; and
(b) determining if the antibody binds to the chimeric norovirus capsid protein;
wherein binding by the antibody to the chimeric norovirus capsid protein identifies the antibody as a neutralizing antibody to a norovirus.

### Claim 25 (depends on 1)

A method of identifying an immunogenic composition that induces a neutralizing antibody to a norovirus in a subject, the method comprising:
(a) contacting a biological sample from a subject that has been administered the immunogenic composition with the chimeric norovirus capsid protein of claim 1;
(b) determining if the biological sample comprises an antibody that binds the chimeric norovirus capsid protein; and
(c) identifying the immunogenic composition as inducing a neutralizing antibody to a norovirus in the subject if the biological sample comprises an antibody that binds to the chimeric norovirus capsid protein.

### Claim 26 (depends on 1)

A method of identifying an immunogenic composition that induces a neutralizing antibody to a norovirus in a subject, the method comprising:
(a) administering an immunogenic composition comprising a norovirus antigen to a subject in an amount effective to induce antibodies against the norovirus antigen;
(b) contacting a biological sample from the subject with the chimeric norovirus capsid protein of claim 1;
(c) determining if the biological sample comprises an antibody that binds the chimeric norovirus capsid protein; and
(d) identifying the immunogenic composition as inducing a neutralizing antibody to a norovirus in the subject if the biological sample comprises an antibody that binds the chimeric norovirus capsid protein.
